Exercise of Warrants, Issue of Equity & TVR

RNS Number : 8311C

RUA Life Sciences PLC

21 October 2020

 

RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Exercise of Warrants

Issue of Equity

and

Total Voting Rights

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), announces that it has received notification from Shore Capital for the exercise of warrants held by Stockdale Securities Limited over 166,667 ordinary shares of 5 pence each in the Company ("Ordinary Shares") at an exercise price of 30 pence per share providing the Company with proceeds of £50,000.10.

Application has therefore been made for 166,667 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on 23 October 2020.

Following Admission, the Company will have 16,353,275 Ordinary Shares in issue and admitted to trading on AIM. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information contact:

RUA Life Sciences

Bill Brown, Chairman                                 Tel: [phone]                                   

David Richmond, CEO    Tel: [phone]   

Shore Capital 

Tom Griffiths/David Coaten                      Tel: [phone]

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon^TM, the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon^TM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

RUA Medical :	End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials :	Licensor of Elast-EonTM polymers to the medical device industry.
RUA Vascular:	Development of large bore polymer sealed grafts and soft tissue patches.
RUA Structural Heart :	Development of tri leaflet polymeric heart valves.

 

END

 

 

IOEMBBATMTTTBMM